Company intelligence / Profile preview

Mygen

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Mygen Therapeutics is a clinical-stage biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. The company has established a comprehensive platform encompassing mRNA sequence optimization, modified nucleotide technology, and proprietary lipid nanoparticle (LNP) delivery systems. Mygen's primary focus areas include oncology, particularly liver cancer, and infectious disease prophylaxis. By integrating R&D with manufacturing capabilities, the company aims to accelerate the translation of mRNA science into effective clinical treatments.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Mygen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mygen.

Explore the full profile